Ranbaxy Laboratories Limited for the year ended December 31, 2002 recorded sales of Rs.2889.40 crore (Rs.2054.50 crore), a growth of 41%. Exports at Rs.1850.30 crore (Rs.1029.10 crore), constituting 64% to total sales, registered a robust growth of 80%. Net sales (after deducting trade discounts) was at Rs. 2768.70 crore (Rs.1942 crore), an increase of 43%. Profit before interest, depreciation and amortisation was Rs.730.50 crore (Rs.392.40 crore), recorded an increase of 86%. Profit before extra-ordinary items was Rs.650.30 crore (Rs.277.80 crore), a growth of 134%. Profit after tax (and deferred tax) was Rs. 623.60 crore (Rs.252 crore), up by 147%.

The Board recommended a final dividend of Rs.10 per share. Earlier in 2002, an interim dividend of Rs. 5 per share was paid on equity shares prior to issue of bonus shares. The total dividend for the year 2002 was Rs. 243.40 crore (2001: Rs. 115.90 crore), an increase of 110%.

For Q1, Ranbaxy Laboratories Limited recorded sales of Rs.10493 crore (Rs.552.90 crore), a growth of 90%, Exports at Rs.829.10 crore (Rs.317.60 crore), constituting 79% to total sales, recorded a buoyant growth of 161%. Net sales (after deducting trade discounts) at Rs.1024.90 crore (Rs.528.90 crore), registered a growth of 94%.

Operating profit before interest, depreciation and amortisation was Rs.342.70 crore (Rs.95.30 crore), an increase of 260%. Operating profit before tax was at Rs.324.20 crore (Rs.62.40 crore), up by 420%. Profit before extra-ordinary items was Rs.329.80 crore (Rs.65.70 crore), recording a growth of 402%. Profit after tax (and deferred tax) was Rs.279.80 crore (Rs.94.90 crore), up by 195%.

Ranbaxy Laboratories Limited and its subsidiaries (Consolidated Global Results) recorded net consolidated sales of Rs.3713.80 crore registering a growth of 38 % (2001: Rs.2685.40 crore). Profit before interest, depreciation and amortisation was Rs.879.60 crore (Rs.486.60 crore), an increase of 81 %. Profit before extra-ordinary items was Rs.745.80 crore (Rs.300.30 crore), a robust growth of 148 %. Profit after tax (including deferred tax) and minority interest was Rs.647 crore (Rs.260.50 crore), up by 148 %.

For Q1, Ranbaxy Laboratories Limited and its subsidiaries (Consolidated Global Results) recorded net consolidated sales of Rs.1110.20 crore, registering a growth of 51% (2001:Rs.734.50 crore). Operating profit before interest, depreciation and amortisation was Rs.262.30 crore (Rs.116.10 crore), an increase of 126%. Operating profit before tax was at Rs.217.40 crore (Rs.66.70 crore) up 226%. Profit before extra-ordinary items was Rs.225.10 crore (Rs.71.80 crore), a robust growth of 214%. Profit after tax (including deferred tax) and minority interest was Rs.172.90 crore (Rs 97.70 crore), up by 77%.
(Conversion to USD at Rs. 47.74 per USD for 2003 and Rs.48.76 per USD for 2002)

Commenting on the business results, D.S.Brar, CEO & Managing Director, Ranbaxy Laboratories Limited said, "Our continuing investments in R&D and important global markets are bringing positive returns. We are looking at ways to further enhance the productivity of our generics business as we embark upon laying a strategic route map for our branded business in the US and some European markets".